Global Pertussis Vaccine Market Valuation and Growth Prospects: $6.49 Billion by 2029

Uncover key drivers, emerging technologies, and competitive movements shaping the pertussis vaccine market from 2025–2034 with trusted insights from The Business Research Company

What Are The Future Growth Projections For The Pertussis Vaccine Market Size?

The pertussis vaccine market has seen consistent expansion in recent years. Its value is projected to climb from $5.5 billion in 2024 to $5.65 billion in 2025, indicating a compound annual growth rate (CAGR) of 2.9%. In the past, this growth was primarily influenced by factors including disease prevalence, the existence of immunization programs, widespread pediatric vaccination, and various regulatory approvals.

The pertussis vaccine market size is anticipated to demonstrate continuous growth over the upcoming years. It is projected to expand to $6.49 billion by 2029, achieving a compound annual growth rate (CAGR) of 3.5%. The expansion during this forecast period is primarily driven by factors such as booster vaccination, maternal immunization, immunization programs for healthcare workers, and various global health initiatives. Key trends expected in the forecast period encompass personalized immunization schedules, the development of combination vaccines, initiatives aimed at vaccine equity, and the integration of digital health solutions for immunization.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13023&type=smp

What Core Market Drivers Are Expanding The Pertussis Vaccine Industry?

The expanding rate of childbirth is anticipated to fuel the growth of the pertussis vaccine market. Childbirth describes the process of a woman giving birth, representing the completion of pregnancy where a fetus develops in the uterus and initiates life outside the womb. The pertussis vaccine is predominantly administered to children to shield them from whooping cough and various severe, potentially fatal conditions. For example, in January 2023, the Centers for Disease Control and Prevention, a US-based national public health organization, released a report indicating that the United States saw a 1% rise in registered births, amounting to 3,664,292, compared to the prior year. Thus, the increasing childbirth rates are a significant impetus for the growth of the pertussis vaccine market.

What Segment Insights Are Highlighted In The Pertussis Vaccine Market Report?

The pertussis vaccine market covered in this report is segmented –

1) By Product Type: DTaP (Diphtheria, Tetanus and Acellular Pertussis) Vaccine, Tdap (Tetanus, Diphtheria and Pertussis) Vaccine

2) By Vaccine Type: Whole-Cell Vaccine, Acellular Vaccine

3) By Application: Children, Adults, Infants

4) By End-User: Vaccination Centers, Hospitals, Clinics

Subsegments:

1) By DTaP (Diphtheria, Tetanus, And Acellular Pertussis) Vaccine: Pediatric DTaP Vaccine, Combination Vaccines With DTaP

2) By Tdap (Tetanus, Diphtheria, And Pertussis) Vaccine: Adolescent Tdap Vaccine, Adult Tdap Vaccine

Which Notable Trends Are Transforming The Pertussis Vaccine Market Outlook?

Leading companies within the pertussis vaccine market are focused on creating novel medications and securing necessary approvals to maintain their competitive standing. As an example, in October 2022, the UK-headquartered pharmaceutical and biotechnology firm, GSK plc., disclosed the approval of BOOSTRIX by the U.S. Food and Drug Administration (FDA). BOOSTRIX is identified as a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap). This vaccine is administered during pregnancy to protect newborn infants from pertussis (whooping cough). Administration involves a single injection into the upper arm muscle. BOOSTRIX has been demonstrated to be both safe and effective for expectant mothers and their babies. Furthermore, it provides effective protection against pertussis, extending to severe instances of the illness.

Which Firms Are Driving Innovation Within The Pertussis Vaccine Market?

Major companies operating in the pertussis vaccine market are Pfizer Inc., Johnson And Johnson Pvt Ltd., Merck And Co. Inc., Novartis AG, GlaxoSmithKline PLC, AstraZeneca PLC, BioNTech SE, Moderna Inc., Sinovac Biotech Ltd., CSL Limited, Astellas Pharma US Inc., Sanofi Pasteur SA, Mitsubishi Tanabe Pharma America Inc., PT Kalbe Farma Tbk, CSL Seqirus, Walvax Biotechnology Co.Ltd., Biological E. Limited, Serum Institute of India, Bavarian Nordic AS, PT Bio Farma, Bharat Biotech International Limited, Takeda Pharmaceutical Company, Panacea Biotec Limited, Beijing Minhai Biotechnology Co. Ltd., Protein Sciences Corporation, Wuhan Institute of Biological Products, Changchun Changsheng Life Sciences, Changsheng Bio-Technology Co. Ltd., Gennova Biopharmaceuticals Ltd., Chiron Corporation.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report

What Regional Trends Are Shaping Growth In The Pertussis Vaccine Market?

North America was the largest region in the pertussis vaccine market in 2024. The regions covered in pertussis vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=13023&type=smp

Browse Through More Reports Similar to the Global Pertussis Vaccine Market 2025, By The Business Research Company

Cancer Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

Dtp Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dtp-vaccine-global-market-report

Companion Animal Veterinary Vaccines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/companion-animal-veterinary-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795